Resources

Your links to the most up-to-date therapeutic information and support.

 

Inappetence Overview

Inappetence can be the first sign, and may be the only sign, a dog is sick or has an underlying health condition. Prolonged inappetence, if left untreated, can become even more detrimental to the patient than the underlying primary disease.

Learn more about inappetence >

Clinical References

Here’s your one-stop source for viewing and downloading ENTYCE® (capromorelin oral solution) white papers, recent clinical studies and more.

Capromorelin increases food consumption and body weight for 4 consecutive days to healthy adult beagle dogs. The objective of this study was to evaluate the effectiveness of capromorelin oral solution (ENTYCE) by measuring increases in appetite and food consumption, measured by food consumption in a randomized, masked, placebo-controlled study with healthy beagle dogs over 4 days.

Download PDF >

A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. This Clinical Field Study evaluated the effectiveness and safety of capromorelin oral solution, (ENTYCE®), a new therapeutic that is a ghrelin receptor agonist, for stimulation of appetite in dogs with reduced appetite.

Download PDF >

Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin, a novel drug for stimulation of appetite. The objective of the study was to evaluate the safety of capromorelin, a ghrelin receptor agonist that stimulates appetite and causes increased body weight and the release of growth hormone.

Download PDF >

Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult beagle dogs. This study’s objective was to determine the effects in dogs of oral capromorelin, a ghrelin receptor agonist, at different doses for 7 days on food consumption, body weight, and serum concentrations of growth hormone, insulin-like growth factor 1, and cortisol.

Download PDF >

ENTYCE (capromorelin oral solution) technical monograph. This resource provides a therapeutic overview of ENTYCE that includes the mechanism of action, clinical use, safety and efficacy data along with a review of inappetence and how to control appetite in dogs.

Download PDF >

In-Clinic Tools

Introducing ENTYCE to your clinic as a therapeutic solution specifically designed to stimulate appetite in dogs.

Dosing Chart

ENTYCE is simple to dose as an oral solution once daily.  Using the 30 mg/ml concentrated solution at 3 mg/kg by mouth once daily equates to an easy-to-remember volume dose of 1 ml per 10 kg.  See this ENTYCE Dosing Chart for appropriate dosing based on weight of dog.

Download PDF >

Inappetence Overview Sheet

Canine inappetence can occur for many reasons and be related to many underlying conditions.  It is equally important to recognize a reduced or altered appetite, not just a complete lack of appetite, to allow the veterinarian to intervene sooner.  Check out this Inappetence Overview Sheet to review the signs, causes and impact.

Download PDF >

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

ENTYCE is Now Available

Other therapeutics from Aratana

Nocita Logo

NOCITA® (bupivacaine liposome injectable suspension)

provides post-operative pain relief for cranial cruciate ligament surgery for up to 72 hours.

Now you can be sure dogs are getting the post-surgical pain relief they need even after they leave your clinic.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.